Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KDOAM-25 citrate 是有效且具有高选择性的组蛋白赖氨酸脱甲基酶 5 (KDM5) 抑制剂,对 KDM5A,KDM5B,KDM5C,KDM5D 的IC50分别为 71 nM,19 nM,69 nM,69 nM。用KDOAM-25 citrate 处理的多发性骨髓瘤 MM1S 细胞显示转录起始位点的整体 H3K4 甲基化增加,增殖受损。
产品描述 | KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC 50 s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. Multiple myeloma MM1S cells treated with KDOAM-25 citrate show increased global H3K4 methylation at transcriptional start sites and impaired proliferation [1]. |
靶点活性 | KDM5A:71 nM , KDM5D:69 nM , KDM5B:19 nM , KDM5C:69 nM |
体外活性 | KDOAM-25 citrate inhibits most potently KDM5B with an IC 50 of ~50 μM and the other KDM5 family members at concentrations above 100 μM. KDOAM-25 citrate is inactive against any of the other tested JmjC family members [1]. KDOAM-25 citrate is able to reduce the viability of MM1S cells with an IC 50 of ~30 μM after a delay of 5-7 days [1]. KDOAM-25 citrate treatment results in a G1 cell-cycle arrest with an increased proportion of MM1S in G1 and a decrease of the proportion of cells in G2 without an increase in the proportion of cells in the apoptotic sub-G1 phase [1]. KDOAM-25 citrate (50 μM) increases with approximately twice as much H3K4me3 in in multiple myeloma cells [1]. |
分子量 | 499.51 |
分子式 | C21H33N5O9 |
CAS No. | 2448475-08-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 200 mg/mL (400.39 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.002 mL | 10.0098 mL | 20.0196 mL | 50.049 mL |
5 mM | 0.4004 mL | 2.002 mL | 4.0039 mL | 10.0098 mL | |
10 mM | 0.2002 mL | 1.001 mL | 2.002 mL | 5.0049 mL | |
20 mM | 0.1001 mL | 0.5005 mL | 1.001 mL | 2.5025 mL | |
50 mM | 0.04 mL | 0.2002 mL | 0.4004 mL | 1.001 mL | |
100 mM | 0.02 mL | 0.1001 mL | 0.2002 mL | 0.5005 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KDOAM-25 citrate 2448475-08-7 Others KDOAM25 citrate KDOAM 25 citrate KDOAM-25 Citrate KDOAM25 Citrate KDOAM 25 Citrate Inhibitor inhibitor inhibit